Table 3

Characteristics of patients in the independent test set 1

Sample ID

Age (years)

Sex

Bacterial isolation

Antibiotherapy before blood collection

Underlying diseases

Survival


Other sepsis (n = 11)

I016*

61

Female

Coagulase-negative staphylococci

Ceftazidime, bactrim, Sulperazole

Hematemesis

Survivor

I017* ‡§

50

Male

Coagulase-negative staphylococci

Ceftriaxone, ceftazidime, doxycycline, cloxacillin

Acute pancreatitis, nephrotic syndrome

Survivor

I018§¶¥

57

Male

Coagulase-negative staphylococci#

Vancomycin

T2D, CRF

Survivor

I019¤

58

Female

Staphylococcus aureus

Cloxacillin, ceftazidime

T2D, wound

Survivor

I020¶¥

66

Female

Coagulase-negative staphylococci#

Ceftazidime, ceftriaxone

T2D, ARF, tuberculosis

Non-survivor

I021

54

Female

Enterococcus spp.

Ceftazidime, cloxacilin

T2D, abscess

Non-survivor

I022§¶

37

Male

Coagulase-negative staphylococci#

Ceftriaxone, ceftazidime

T2D, ARF

Non-survivor

I023¶¤

70

Female

E. coli

Doxycycline, ceftazidime

T2D

Non-survivor

I024¶¥

56

Male

Coagulase-negative staphylococci

Meropenem, ceftazidime

T2D, RF

Survivor

I025*

50

Male

S. pneumoniae

Ceftriaxone, meropenem

T2D

Non-survivor

I026

57

Male

K. pneumoniae

Ceftriaxone, ceftazidime, bactrim

T2D

Survivor

Septicemic melioidosis (n = 13)

M016

39

Male

B. pseudomallei

Ceftazidime, bactrim, doxycycline

T2D

Survivor

M017

52

Female

B. pseudomallei

Norfloxacin, ceftazolin

T2D

Survivor

M020

61

Male

B. pseudomallei

Ceftriaxone, doxycycline, ceftazidime

-

Survivor

M021

56

Female

B. pseudomallei

Ceftriaxone, ceftazidime

T2D

Survivor

M022

18

Male

B. pseudomallei

Ceftazidime, cactrim

T2D

Survivor

M023

63

Male

B. pseudomallei

Bactrim, ceftazidime

T2D

Survivor

M024

44

Male

B. pseudomallei

Meropenem

T2D, RF

Survivor

M025

57

Male

B. pseudomallei

Ceftazidime

T2D

Survivor

M026

48

Male

B. pseudomallei

Ceftazidime, doxycycline, bactrim

T2D

Survivor

M027

44

Male

B. pseudomallei

Ceftriaxone, ceftazidime, meropenem

ARF

Survivor

M028

70

Male

B. pseudomallei

Ceftazidime, levofloxacin, bactrim

T2D

Survivor

M029

50

Male

B. pseudomallei

Ceftriaxone, ceftazidime

CRF

Non-survivor

M030

44

Male

B. pseudomallei

Ceftazidime, ceftriazone

T2D, tuberculosis

Survivor


*Hospital-acquired septicemia;long hospitalization;taken immunosuppressive drugs;§dialysis; community-acquired septicemia; ¥mechanical ventilation; ¤wounds. #Positive by two sets of blood cultures. ARF, acute renal failure; CRF, chronic renal failure; RF, renal failure; T2D, type 2 diabetes.

Pankla et al. Genome Biology 2009 10:R127   doi:10.1186/gb-2009-10-11-r127

Open Data